Wire · opportunities
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
FDA approves Freenome's SimpleScreen CRC blood-based colorectal cancer screening test with 81% sensitivity for cancer detection; Abbott gains exclusive US commercialisation rights and receives $100m milestone payment, with Medicare coverage and American Cancer Society guideline inclusion expected.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 4 sources have reported it between 27 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
Abbott just acquired Freenome's market position without acquiring Freenome itself - they own the exclusive US route to 60 million unscreened patients via a test that now has Medicare reimbursement and guideline backing. If you make upstream components for blood-based cancer screening (sample collection, lab infrastructure, AI signal processing), Abbott's scale just became your customer.
◆ Coverage
4 sources · first reported 27 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics